Ambry Genetics Corporation

Ambry Genetics Corporation is a US-based company specializing in advanced genetic testing solutions, focusing on the identification and analysis of genetic variants related to health conditions. Ambry Genetics Corporation, founded in 1999 in Aliso Viejo, US, offers genetic testing services to healthcare professionals. The company was acquired in July 2017 by INCJ and Konica Minolta Healthcare Americas, Inc. with initial funding of USD 800 mn, which will be followed by an additional USD 200 mn payment.

Aaron Elliott and Tom Schoenherr currently serve as CEOs. Ambry Genetics specializes in advanced genetic testing solutions, focusing on the identification and analysis of genetic variants associated with various health conditions. Their core offerings include paired DNA/RNA testing with the innovative +RNAinsight®, which evaluates functional RNA data to enhance the detection and classification of DNA variants. Additionally, Ambry provides exome testing through its Patient for Life program, allowing for proactive reanalysis of genetic findings as new gene-disease relationships are established, ensuring that patients receive the most current information at no extra cost.

The Ambry CARE Program® serves as a comprehensive digital health solution aimed at identifying high-risk patients who may benefit from genetic testing, delivering patient education, and streamlining test ordering and result reporting. The company primarily serves healthcare professionals and institutions across the United States and Canada, helping them make informed decisions for patient care while addressing the needs of diverse populations. Ambry Genetics generates revenue through a structured model that includes direct transactions with healthcare providers and institutions for genetic testing services. Their offerings, such as the Patient for Life program and the Ambry CARE Program®, facilitate ongoing patient engagement and education, contributing to the company's revenue streams.

The transaction structure typically involves contracts with healthcare providers who order testing on behalf of patients, ensuring seamless integration into patient care workflows. By providing advanced testing solutions, Ambry supports healthcare providers in identifying necessary tests, promoting proactive healthcare management. The company's commitment to affordability is evident in their efforts to ensure that no qualified patient is deterred by cost considerations, making their services accessible to a wide range of users. Ambry Genetics plans to utilize the recent funding from the acquisition to expand its service offerings.

This strategy includes the development of upcoming products, although specific release dates are not mentioned. The company is also targeting expansion into new markets and geographic regions to enhance its reach. The acquisition funding of USD 1,000 mn will support these initiatives and bolster Ambry's capabilities in delivering genetic testing solutions.